SG11201901355SA - Methods of treating severe insulin resistance by interfering with glucagon receptor signaling - Google Patents

Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Info

Publication number
SG11201901355SA
SG11201901355SA SG11201901355SA SG11201901355SA SG11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA SG 11201901355S A SG11201901355S A SG 11201901355SA
Authority
SG
Singapore
Prior art keywords
international
tarrytown
insulin resistance
severe insulin
new york
Prior art date
Application number
SG11201901355SA
Other languages
English (en)
Inventor
Jesper Gromada
Haruka Okamoto
Stephen Jaspers
Joyce Harp
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59799505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201901355S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201901355SA publication Critical patent/SG11201901355SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201901355SA 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling SG11201901355SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381263P 2016-08-30 2016-08-30
US201662411032P 2016-10-21 2016-10-21
PCT/US2017/049137 WO2018044903A1 (en) 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Publications (1)

Publication Number Publication Date
SG11201901355SA true SG11201901355SA (en) 2019-03-28

Family

ID=59799505

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201901355SA SG11201901355SA (en) 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
SG10201913074WA SG10201913074WA (en) 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913074WA SG10201913074WA (en) 2016-08-30 2017-08-29 Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Country Status (13)

Country Link
US (3) US10995146B2 (enExample)
EP (1) EP3506940A1 (enExample)
JP (3) JP7173962B2 (enExample)
KR (3) KR102708864B1 (enExample)
CN (2) CN118236497A (enExample)
AU (2) AU2017321423C1 (enExample)
CA (1) CA3034777A1 (enExample)
IL (2) IL322691A (enExample)
MA (1) MA46089A (enExample)
MX (2) MX385598B (enExample)
NZ (1) NZ750953A (enExample)
SG (2) SG11201901355SA (enExample)
WO (1) WO2018044903A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7173962B2 (ja) 2016-08-30 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
MX2021008797A (es) * 2019-01-23 2022-01-31 Regeneron Pharma Tratamiento de afecciones oftalmicas con inhibidores de proteinas relacionadas a angiopoyetina 7 (angptl7).
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
US12398202B2 (en) 2019-09-04 2025-08-26 Apharma Use of ITIH1 as biomarker for detection of insulin resistance in diseases accompanied by impaired glucose tolerance
CN113481290B (zh) * 2021-06-30 2022-08-23 华南农业大学 一种klf4基因在制备检测和/或减少母鼠不良妊娠结局的产品中的应用
CN114342875A (zh) * 2022-01-12 2022-04-15 吉林大学 一种新型妊娠糖尿病动物模型的建立方法
EP4708502A1 (en) 2023-08-21 2026-03-11 LG Energy Solution, Ltd. Cell assembly, battery module including same, and method for manufacturing cell assembly

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
PL178685B1 (pl) 1992-08-28 2000-06-30 Zymogenetics Inc Cząsteczka DNA kodująca receptor glukagonu lub peptyd receptora glukagonu, konstrukty DNA, komórka gospodarza zawierająca konstrukty DNA, peptyd receptora glukagonu i sposoby wytwarzania receptora glukagonu lub peptydu receptora glukagonu
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7301036B2 (en) 2003-12-19 2007-11-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CN1964947A (zh) 2004-06-04 2007-05-16 默克公司 吡唑衍生物、包含其的组合物及其用法
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
JP2008505905A (ja) 2004-07-07 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
CA2574147A1 (en) 2004-07-22 2006-02-09 Linda Brockunier Substituted pyrazoles, compositions containing such compounds and methods of use
PL1856090T3 (pl) 2005-02-11 2010-02-26 Lilly Co Eli Podstawione pochodne tiofenu jako antagoniści receptora glukagonu, ich wytwarzanie i terapeutyczne zastosowania
CN101146762A (zh) 2005-03-21 2008-03-19 默克公司 取代的芳基和杂芳基衍生物
WO2006104826A2 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AU2007240315A1 (en) 2006-04-20 2007-11-01 Amgen Inc. GLP-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2008098244A1 (en) 2007-02-09 2008-08-14 Metabasis Therapeutics, Inc. Novel antagonists of the glucagon receptor
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
CA2724294A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8445538B2 (en) 2008-12-19 2013-05-21 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
WO2010088061A1 (en) 2009-01-28 2010-08-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010093535A1 (en) 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098948A1 (en) 2009-02-13 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containin such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2758533B1 (en) 2011-09-20 2018-04-11 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
WO2014181229A2 (en) 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
BR112017005110A2 (pt) * 2014-09-16 2018-01-23 Regeneron Pharma anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
JP7173962B2 (ja) 2016-08-30 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法

Also Published As

Publication number Publication date
AU2017321423C1 (en) 2025-01-30
KR20190044079A (ko) 2019-04-29
US12624116B2 (en) 2026-05-12
AU2024278594A1 (en) 2025-01-30
SG10201913074WA (en) 2020-03-30
IL322691A (en) 2025-10-01
WO2018044903A1 (en) 2018-03-08
JP2019528306A (ja) 2019-10-10
CA3034777A1 (en) 2018-03-08
KR20240110661A (ko) 2024-07-15
CN118236497A (zh) 2024-06-25
IL264879A (enExample) 2019-04-30
US10995146B2 (en) 2021-05-04
JP7633213B2 (ja) 2025-02-19
US20210221896A1 (en) 2021-07-22
AU2017321423A1 (en) 2019-03-14
US20230416384A1 (en) 2023-12-28
KR20230062673A (ko) 2023-05-09
IL264879B1 (en) 2026-03-01
EP3506940A1 (en) 2019-07-10
US20190218301A1 (en) 2019-07-18
US11708416B2 (en) 2023-07-25
JP2022140605A (ja) 2022-09-26
JP2024178249A (ja) 2024-12-24
AU2017321423B2 (en) 2024-09-26
CN109922831A (zh) 2019-06-21
MA46089A (fr) 2019-07-10
NZ750953A (en) 2026-02-27
KR102708864B1 (ko) 2024-09-25
MX2021006457A (es) 2021-07-02
MX2019002437A (es) 2019-10-09
MX385598B (es) 2025-03-18
RU2019107807A3 (enExample) 2021-05-18
JP7173962B2 (ja) 2022-11-16
RU2019107807A (ru) 2020-10-01

Similar Documents

Publication Publication Date Title
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201806992VA (en) Antibodies to tigit
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201906947SA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907922PA (en) Cd19 compositions and methods for immunotherapy
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201905699XA (en) Anti-icos agonist antibodies and uses thereof
SG11201900596XA (en) Cannabis composition
SG11201900501RA (en) Cannabis composition
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201908796XA (en) Improved antigen binding receptors
SG11201908391XA (en) Methods for modulating an immune response
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201903674YA (en) Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201908919XA (en) Combination therapies targeting pd-1, tim-3, and lag-3
SG11201909856XA (en) Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
SG11201805579SA (en) Recombinant igg fc multimers
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201407548UA (en) Treatment of amd using aav sflt-1
SG11201900154VA (en) Compounds, compositions, and methods for the treatment of disease
SG11201906837PA (en) A drug monitoring tool